hotspot -WSS

hotspot

author：explore 2025-09-30 23:40:37 - browse：5611

gantenerumab Alzheimer's disease Roche — Sebastien Bozon/AFP via Getty Images

LONDON — Roche on Thursday said its recently acquired experimental obesity medication helped people lose a significant amount of weight in an early trial, sending its shares up in early trading.

The drug, a once-weekly injection known as CT-388, resulted in an average placebo-adjusted weight loss of 18.8% after 24 weeks, the company said. The study was a Phase 1 trial, though it was placebo-controlled.

The reaction to such an early result — Roche shares were up roughly 4% early Thursday — is a signal both of the stakes of the obesity medication race and the keen interest investors have in the field.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： An outrageous hospital charge: I paid $710 for an hour of babysitting

hotspot

WSS

McConnell had minor fall 2 weeks ago, uses wheelchair periodically to get around: Sources

'Investigate these claims': UFO transparency at center of House hearing

Ending health disparities requires full federal government, panel says

'Hero' Louisville officer shot in head at mass shooting discharged over 3 months later

STAT Report: Patient voices and perspectives

Behind warning on Apellis’s eye drug lies a conflict of interest

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

Jerome Adams on the need for new antivirals for Covid

Biden jokes that Republicans may impeach him because inflation is starting to cool down

After affirmative action ruling, medical educators look to 'holistic review'

The mammogram wars are not over

Activists slam private health insurers over coverage restrictions

Behind warning on Apellis’s eye drug lies a conflict of interest

Novavax promises a turnaround & Lilly roils the obesity market

Why patients can’t get everything they want on drug pricing

Wikipedia

Truvian presents data for its desktop blood

Ford recalls 870K F

CDC: Cases of alpha

Bryan Kohberger seeks indictment dismissal in Idaho college killings case

The mammogram wars are not over

What it's like to live with paralysis for one psychologist

entertainment

hotspot

Wikipedia

entertainment